Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, appointed Matthias Schroff CEO. Schroff will also join the board of directors. He succeeds Shailesh Maingi, who will remain as executive chairman.

Schroff has extensive biopharmaceutical leadership experience with a track record of success building companies and developing new medicines in immuno-oncology, inflammatory diseases, and genetic disorders. Schroff was most recently CEO of Exicure, a publicly traded biotechnology company developing gene regulatory and immunotherapeutic drugs.

Prior to his role at Exicure, Schroff was the CEO of Vaximm AG and held several positions on management levels at Mologen, ultimately rising to CEO.

“I am excited about the next chapter for the company under Matthias’s leadership,” said Maingi. “I am proud of the team we have built and all that we have accomplished together. Matthias’s background and expertise in leading teams to success is a perfect fit for this stage of Inceptor’s growth.”

“I am thrilled to be taking on this new role at such an important time,” said Schroff. “Inceptor Bio’s commitment to advancing a diversified pipeline of cell therapies is highly differentiated, and I am excited to join the team at this important inflection point.”